Share on StockTwits

Kindred Biosciences (NYSE:KIN) Director Ernest Mario purchased 10,000 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were purchased at an average cost of $10.55 per share, for a total transaction of $105,500.00. Following the completion of the transaction, the director now directly owns 52,500 shares in the company, valued at approximately $553,875. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at BMO Capital Markets cut their price target on shares of Kindred Biosciences from $30.00 to $19.00 in a research note on Thursday, August 21st. Separately, analysts at Leerink Swann cut their price target on shares of Kindred Biosciences from $29.00 to $11.25 in a research note on Thursday, August 21st. Finally, analysts at Roth Capital cut their price target on shares of Kindred Biosciences to $11.50 in a research note on Thursday, August 21st. Two equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $13.92.

Kindred Biosciences (NYSE:KIN) traded up 2.45% on Thursday, hitting $10.89. 63,467 shares of the company’s stock traded hands. Kindred Biosciences has a 52 week low of $8.75 and a 52 week high of $26.99. The stock has a 50-day moving average of $14.23 and a 200-day moving average of $17.61. The company’s market cap is $214.7 million.

Kindred Biosciences (NYSE:KIN) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.42) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.35) by $0.07. On average, analysts predict that Kindred Biosciences will post $-1.75 earnings per share for the current fiscal year.

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.